185 related articles for article (PubMed ID: 15951029)
1. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
Hu K; Clément JF; Abrahamyan L; Strebel K; Bouvier M; Kleiman L; Mouland AJ
J Virol Methods; 2005 Sep; 128(1-2):93-103. PubMed ID: 15951029
[TBL] [Abstract][Full Text] [Related]
2. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
3. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing.
Bardy M; Gay B; Pébernard S; Chazal N; Courcoul M; Vigne R; Decroly E; Boulanger P
J Gen Virol; 2001 Nov; 82(Pt 11):2719-2733. PubMed ID: 11602784
[TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.
Kotler M; Simm M; Zhao YS; Sova P; Chao W; Ohnona SF; Roller R; Krachmarov C; Potash MJ; Volsky DJ
J Virol; 1997 Aug; 71(8):5774-81. PubMed ID: 9223465
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.
Baraz L; Friedler A; Blumenzweig I; Nussinuv O; Chen N; Steinitz M; Gilon C; Kotler M
FEBS Lett; 1998 Dec; 441(3):419-26. PubMed ID: 9891983
[TBL] [Abstract][Full Text] [Related]
6. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
[TBL] [Abstract][Full Text] [Related]
8. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
Ho SK; Coman RM; Bunger JC; Rose SL; O'Brien P; Munoz I; Dunn BM; Sleasman JW; Goodenow MM
Virology; 2008 Sep; 378(2):272-81. PubMed ID: 18599104
[TBL] [Abstract][Full Text] [Related]
9. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region.
Baraz L; Hutoran M; Blumenzweig I; Katzenellenbogen M; Friedler A; Gilon C; Steinitz M; Kotler M
J Gen Virol; 2002 Sep; 83(Pt 9):2225-2230. PubMed ID: 12185277
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
13. Bioluminescence technologies to detect calicivirus protease activity in cell-free system and in infected cells.
Oka T; Takagi H; Tohya Y; Murakami K; Takeda N; Wakita T; Katayama K
Antiviral Res; 2011 Apr; 90(1):9-16. PubMed ID: 21316392
[TBL] [Abstract][Full Text] [Related]
14. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F; Martinez R; Peters S; Sudre P; Telenti A
AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
[TBL] [Abstract][Full Text] [Related]
15. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
Lindhofer H; von der Helm K; Nitschko H
Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
[TBL] [Abstract][Full Text] [Related]
16. Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function.
Khan MA; Akari H; Kao S; Aberham C; Davis D; Buckler-White A; Strebel K
J Virol; 2002 Sep; 76(18):9112-23. PubMed ID: 12186895
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation.
Hsieh SH; Yu FH; Huang KJ; Wang CT
J Virol; 2023 Sep; 97(9):e0094823. PubMed ID: 37671867
[TBL] [Abstract][Full Text] [Related]
19. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
[TBL] [Abstract][Full Text] [Related]
20. A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease.
Breuer S; Sepulveda H; Chen Y; Trotter J; Torbett BE
Biochemistry; 2011 May; 50(20):4371-81. PubMed ID: 21452835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
